Tadrist Abel, Baboudjian Michael, Bah Mamadou B, Alegorides Camille, Bottet Florie, Arroua Frederic, Eghazarian Christophe, Fourmarier Marc
Department of Urology, CH Aix-Pertuis, Aix en Provence, France.
Department of Urology, North Hospital, Aix-Marseille University, APHM, Marseille, France.
Int Urol Nephrol. 2023 Feb;55(2):249-253. doi: 10.1007/s11255-022-03408-w. Epub 2022 Nov 7.
To report the efficacy and safety of water vapor thermal therapy to achieve catheter removal in frail patients with refractory acute urinary retention.
Data from consecutive frail patients with indwelling urinary catheter undergoing the Rezūm™ therapy (Boston Scientific Corporation, Marlborough, MA) at a single center between October 2017 and June 2021 were prospectively collected. The included patients were deemed unfit or at high risk of complications for conventional benign prostatic hyperplasia (BPH) surgery. Prostate volumes up to 120 mL were considered eligible. The primary endpoint was successful cessation of catheter dependency, assessed postoperatively and up to 1 year of follow-up.
A total of 24 men met our inclusion criteria. The median age, Charlson comorbidity index, and duration of preoperative catheterization were 77 years (IQR 67-86), 6 (IQR 3-7), and 113 days (IQR 87-159), respectively. Two cases (8.3%) of postoperative complications were recorded (Clavien II and Clavien IIIa). After a median postoperative catheterization time of 21 days (IQR 11-32), all patients regained spontaneous voiding. During follow-up, two patients died and a total of 22 patients completed the 1 year follow-up. All patients maintained spontaneous voiding without recurrence of urinary retention. No surgical retreatment was performed. In terms of pharmacological management, 22/24 patients (91.7%) had a BPH medication pre-Rezūm™; this decreased to 8/22 patients (36.3%) post-Rezūm™ (p < 0.001).
In this single-institution, prospective, and observational study, water vapor thermal therapy was found to be effective and safe in restoring successful spontaneous voiding in a cohort of elderly and frail patients.
报告水蒸气热疗法在体弱的难治性急性尿潴留患者中实现拔除导尿管的有效性和安全性。
前瞻性收集了2017年10月至2021年6月期间在单一中心接受Rezūm™疗法(波士顿科学公司,马萨诸塞州马尔伯勒)的连续体弱的留置导尿管患者的数据。纳入的患者被认为不适合进行传统的良性前列腺增生(BPH)手术或有并发症的高风险。前列腺体积达120 mL被认为符合条件。主要终点是成功停止依赖导尿管,在术后及长达1年的随访中进行评估。
共有24名男性符合我们的纳入标准。中位年龄、查尔森合并症指数和术前导尿持续时间分别为77岁(四分位间距67 - 86)、6(四分位间距3 - 7)和113天(四分位间距87 - 159)。记录到2例(8.3%)术后并发症(Clavien II级和Clavien IIIa级)。术后中位导尿时间为21天(四分位间距11 - 32),所有患者恢复自主排尿。在随访期间,2例患者死亡,共有22例患者完成了1年随访。所有患者均维持自主排尿,无尿潴留复发。未进行手术再治疗。在药物治疗方面,22/24例患者(91.7%)在Rezūm™治疗前服用BPH药物;这一比例在Rezūm™治疗后降至8/22例患者(36.3%)(p < 0.001)。
在这项单机构、前瞻性、观察性研究中,发现水蒸气热疗法在一组老年体弱患者中恢复成功自主排尿方面是有效且安全的。